Shandong Boan Biotechnology Past Earnings Performance
Past criteria checks 2/6
Shandong Boan Biotechnology has been growing earnings at an average annual rate of 55.3%, while the Biotechs industry saw earnings growing at 48.4% annually. Revenues have been growing at an average rate of 20.3% per year. Shandong Boan Biotechnology's return on equity is 1.6%, and it has net margins of 4.2%.
Key information
55.28%
Earnings growth rate
111.50%
EPS growth rate
| Biotechs Industry Growth | 11.00% |
| Revenue growth rate | 20.26% |
| Return on equity | 1.58% |
| Net Margin | 4.23% |
| Last Earnings Update | 30 Jun 2025 |
Recent past performance updates
Recent updates
Shandong Boan Biotechnology's (HKG:6955) Anemic Earnings Might Be Worse Than You Think
Oct 06
The Market Doesn't Like What It Sees From Shandong Boan Biotechnology Co., Ltd.'s (HKG:6955) Revenues Yet As Shares Tumble 27%
Sep 08Shandong Boan Biotechnology Co., Ltd.'s (HKG:6955) Price Is Right But Growth Is Lacking After Shares Rocket 31%
Jul 24We Think Shandong Boan Biotechnology (HKG:6955) Is Taking Some Risk With Its Debt
May 23Shandong Boan Biotechnology Co., Ltd.'s (HKG:6955) 48% Price Boost Is Out Of Tune With Revenues
Apr 17Investor Optimism Abounds Shandong Boan Biotechnology Co., Ltd. (HKG:6955) But Growth Is Lacking
Mar 26Revenue & Expenses Breakdown
How Shandong Boan Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 25 | 757 | 32 | 357 | 122 |
| 31 Mar 25 | 742 | 53 | 345 | 136 |
| 31 Dec 24 | 726 | 73 | 332 | 149 |
| 30 Sep 24 | 723 | 67 | 328 | 170 |
| 30 Jun 24 | 720 | 62 | 323 | 190 |
| 31 Mar 24 | 669 | -29 | 316 | 211 |
| 31 Dec 23 | 618 | -119 | 308 | 231 |
| 30 Sep 23 | 587 | -209 | 305 | 294 |
| 30 Jun 23 | 557 | -298 | 302 | 357 |
| 31 Mar 23 | 536 | -315 | 299 | 379 |
| 31 Dec 22 | 516 | -332 | 296 | 400 |
| 30 Sep 22 | 442 | -291 | 253 | 345 |
| 30 Jun 22 | 367 | -251 | 211 | 289 |
| 31 Mar 22 | 263 | -238 | 153 | 260 |
| 31 Dec 21 | 159 | -225 | 96 | 232 |
Quality Earnings: 6955 has high quality earnings.
Growing Profit Margin: 6955's current net profit margins (4.2%) are lower than last year (8.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6955 has become profitable over the past 5 years, growing earnings by 55.3% per year.
Accelerating Growth: 6955's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 6955 had negative earnings growth (-48.2%) over the past year, making it difficult to compare to the Biotechs industry average (-4.1%).
Return on Equity
High ROE: 6955's Return on Equity (1.6%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/06 10:58 |
| End of Day Share Price | 2025/12/05 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shandong Boan Biotechnology Co., Ltd. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Chen Chen | UBS Investment Bank |